国产创新药新适应症密集获批 “一药拓多域”重塑行业成长逻辑

格隆汇
Sep 11
创新药行业正迎来一轮新适应症集中扩容的窗口。国内药企多款创新药接连获批新适应症,一些全球重磅药物亦不断突破原有疾病适用边界,“一药拓多域”正成为国内外普遍采取的开发策略。单一适应症的创新药,在上市后很容易触及销售天花板。而一些具备持续适应症拓展潜力的品种,则能够拉长产品生命周期、摊薄研发与商业化成本,也有望重塑创新药管线的成长逻辑。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10